Guide on the Pharmdevgroup drug development services
Pharmdevgroup drug development service provides comprehensive drug discovery services ranging from Hit Identification/Target Validation (HI/TV) through Lead Optimization (LO)/Pre-clinical Candidate (PCC) for a wide range of therapeutic areas, including oncology. Pharmdevgroup as an integrated has quickly established itself as a leading collaborator for biotechnology and pharmaceutical companies around the world, thanks to its well-enabled capabilities in oncology, metabolic disorders, central nervous system, pain, inflammation, fibrosis, and respiratory diseases.
With extensive experience in each of these therapeutic areas, PharmDevGroup has amassed extensive expertise in the fields of discovery informatics, computational chemistry/molecular modelling, pharmaceutical and structural biology, as well as both in-vitro and in-vivo pharmacology, as well as the translational sciences.
Early-stage lead generation across a variety of target classes is the primary focus of the team's efforts in the drug discovery process. They employ a variety of technologies, including high throughput screening, molecular modelling, medicinal chemistry, structural biology, and computational chemistry, to identify novel start points that are then selectively progressed through the pre-clinical discovery process and into clinical trials. Our experience in animal pharmacology, along with the availability of different PD and disease models, assists us.
- Expertise that has been demonstrated: Approximately 50 programmes have resulted in pre-clinical decision results, with some resulting in effective clinical outcomes across a variety of treatment domains on drug development services.
- Findings from exploratory and translational research across target and disease platforms that allow researchers to take "right shots at the objective"
- Portfolio management for pre-clinical and "early-stage POC" research that is integrated and robust
A Customized Approach
Pharmdevgroup is a bespoke solution provider for the biotechnology and pharmaceutical industries, providing unique solutions throughout the drug discovery value chain to these industries. We provide flexibility via the following business models to meet the needs of each customer in the most efficient manner:
Pharmdevgroup partners with some of the world's most prestigious pharmaceutical and biotechnology businesses, as well as academic institutions and research organisations. Pharmdevgroup has been able to achieve important results in a very short amount of time because of innovative and rigorous research, quality in execution, and total integrity, all of which have been paired with adaptable business models. The development of value for partners is the defining characteristic of the Pharmdevgroup drug development service collaborative model.
CAR-T/TCR and other cellular treatments, monoclonal and bi-specific antibodies, fusion proteins, and biosimilars/biobetters are just a few of the big molecule pharmaceuticals that Pharmdevgroup helps in the bioanalytical development stage. We are a full-service GLP/GCP and CLIA contract research business that offers a variety of services.
1 people like it
Comments